New PKU formula shows promise in managing blood levels
NCT ID NCT05827536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new amino acid formula called PKU GOLIKE in people aged 16 and older with phenylketonuria (PKU). The goal was to see if it could better control daily swings in blood phenylalanine levels compared to standard treatment. The study was stopped early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHENYLKETONURIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo, Via Antonio di Rudinì 8
Milan, 20142, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene infusion rewrite the fate of PKU?
- Newborn screening study aims to catch rare diseases at birth
- PKU Drug's nutritional impact under the microscope
- PKU diet in childhood may shape adult IQ, study finds
- New PKU drink passes small taste and tolerance test
- New gene therapy aims to tame PKU in first human test